Pfizer has submitted a sweetened bid for Metsera, an obesity drug developer, as its fight against rival Novo Nordisk ...
The new offer improves upon Pfizer’s earlier proposal for US$86.20 (RM359.97) a share including milestone payments, said the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback